FDA warns Spain's Bacalao Giraldo over inadequate HACCP controls for Clostridium botulinum in refrigerated and frozen desalted cod.
What happened
FDA inspected the seafood processing facility in Legutiano, Álava, Spain, on May 20 and 21, 2024, and issued an FDA-483 listing observations. FDA found serious violations of the seafood HACCP regulation in the company's HACCP plans for refrigerated and frozen desalted cod in modified atmosphere/reduced oxygen packaging. The company responded on June 10 and 11, July 18, and August 26, 2024, but FDA found the responses inadequate.
What FDA found
The HACCP plan's oxygen critical limit for modified atmosphere packaging was not adequate to control Clostridium botulinum growth and toxin formation during distribution.
21 CFR 123.6(c)(3)The HACCP plan for refrigerated desalted cod in reduced oxygen packaging did not list the refrigerated finished product storage step as a critical control point for Clostridium botulinum.
21 CFR 123.6(a) and (c)(2)The HACCP plan did not list undeclared allergens as a food safety hazard and did not include a control to ensure labels list major food allergens such as cod.
21 CFR 123.6(a) and (c)(1)
What FDA wants
FDA tells the company to respond in writing within 15 working days of receiving the letter with the specific corrections, including a copy of the hazard analysis and HACCP plan for desalted cod in ROP and five consecutive days of completed monitoring records for five production date codes. If corrections cannot be completed in that time, the company must explain the delay and state when it will correct remaining violations.
Who should pay attention
- U.S. importers and brands that buy desalted cod from this Spanish processor
- foreign seafood processors that pack refrigerated or frozen fish in reduced oxygen packaging
- quality teams responsible for seafood HACCP plans and allergen labeling
This is a summary. Read the original letter on fda.gov.